Migraine News and Research

Latest Migraine News and Research

Allergan receives positive opinion from Irish Medicines Board for BOTOX

Allergan is pleased to announce that BOTOX has received a positive opinion from the Irish Medicines Board for the management of urinary incontinence in adults with neurogenic detrusor overactivity (NDO) resulting from neurogenic bladder due to stable sub-cervical spinal cord injury, or multiple sclerosis.

8 Aug 2011

Longer looks: Treating Down syndrome?; mentally ill, meds & trials

Politicians want to lower spending, or at least they say they do. But in all the to-and-fro over raising the debt ceiling, little sensible has been said about lowering spending in the long term. Nothing illuminates this more clearly than health care.

5 Aug 2011

FDA accepts MAP Pharmaceuticals' LEVADEX NDA for filing

MAP Pharmaceuticals, Inc. today announced that its New Drug Application (NDA) for LEVADEX® orally inhaled migraine drug for the potential acute treatment of migraine in adults has been accepted for filing by the U.S. Food and Drug Administration (FDA), with a goal date of March 26, 2012 under the Prescription Drug User Fee Act (PDUFA).

2 Aug 2011

Smoking, high blood pressure and diabetes in middle age linked to brain damage

A new study suggests smoking, high blood pressure, diabetes and being overweight in middle age may cause brain shrinkage and lead to cognitive problems up to a decade later.

2 Aug 2011

Statins may help protect young people from future strokes

New research indicates cholesterol lowering drugs known as statins may help prevent future strokes among young people who have already had a stroke.

2 Aug 2011

Merck reports worldwide sales of $12.2 billion for second quarter 2011

Merck, known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2011.

29 Jul 2011

POZEN reports revenue of $4.6 million for second quarter 2011

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the second quarter ended June 30, 2011.

28 Jul 2011

Cognitive behavioral therapy and self-help may improve unexplained symptoms of pain, fatigue

A new type of therapy may help people with symptoms such as pain, weakness, or dizziness that can't be explained by an underlying disease, according to a study published in the July 27, 2011, online issue of Neurology, the medical journal of the American Academy of Neurology.

28 Jul 2011

Safeguard Scientifics reports consolidated net income of $121.8M for second quarter 2011

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced results of operations for the second quarter of 2011.

27 Jul 2011

Baxter GAMMAGARD LIQUID for PI receives FDA approval for subcutaneous administration

Baxter International Inc. announced today that the U.S. Food and Drug Administration has approved the subcutaneous administration of GAMMAGARD LIQUID 10% [Immune Globulin Infusion (Human)] for patients with primary immunodeficiency.

From Baxter International Inc. 25 Jul 2011

FDA approves Cephalon's REMS for FENTORA, ACTIQ

Cephalon, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the Risk Evaluation and Mitigation Strategy (REMS) for FENTORA and ACTIQ.

22 Jul 2011

Public disclosure of Bachmann's migraine condition raises much-needed awareness

University of Vermont Professor of Neurology and migraine expert Robert Shapiro, M.D., Ph.D., says U.S. Representative and presidential candidate Michele Bachmann's public disclosure of her migraine condition has brought much-needed awareness to this disabling, often-stigmatized disorder, which afflicts millions of Americans.

21 Jul 2011

Study examines cost-effectiveness of MS drugs in the U.S.

A new study examining the cost-effectiveness of drugs to treat multiple sclerosis (MS) in the United States finds that the health gains from these drugs come at a very high cost compared to basic therapy to control the symptoms of MS and compared to treatments for other chronic diseases.

21 Jul 2011

Scientists analyze structural changes in calcium channels caused by Timothy-mutation

The human genome encodes 243 voltage-gated ion channels. Mutations in calcium channels can cause severe inherited diseases such as migraine, night blindness, autism spectrum disorders and Timothy syndrome, which leads to severe cardiovascular disorders.

15 Jul 2011

Maintaining general health may help reduce risk for dementia

Improving and maintaining health factors not traditionally associated with dementia, such as denture fit, vision and hearing, may lower a person's risk for developing dementia, according to a new study published in the July 13, 2011, online issue of Neurology®, the medical journal of the American Academy of Neurology.

14 Jul 2011

UW scientists determine atomic architecture of sodium channel

Scientists at the University of Washington (UW) in Seattle have determined the atomic architecture of a sodium channel. The achievement opens new possibilities for molecular medicine researchers around the world in designing better drugs for pain, epilepsy, and heart rhythm disturbances.

14 Jul 2011

FDA clears St. Jude Medical's Epiducer lead delivery system for neurostimulation

St. Jude Medical, Inc., a global medical device company, today announced the U.S. Food and Drug Administration (FDA) clearance and limited market release of the Epiducer lead delivery system for neurostimulation therapy.

13 Jul 2011

Osteoporosis, low bone density common in people with early-stage MS

Osteoporosis and low bone density are common in people in the early stages of multiple sclerosis (MS), according to a new study published in the July 12, 2011, print issue of Neurology, the medical journal of the American Academy of Neurology.

12 Jul 2011

FDA approves expansion of St. Jude Medical's BROADEN deep brain stimulation study for depression

St. Jude Medical, Inc., a global medical device company, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for expansion of its BROADEN (BROdmann Area 25 DEep brain Neurostimulation) study for depression. This expansion will allow a maximum of 20 sites across the U.S. to enroll up to 125 patients.

11 Jul 2011

Study links OBEs with neural instability and errors in body representation

Although out-of-body experiences (OBEs) are typically associated with migraine, epilepsy and psychopathology, they are quite common in healthy and psychologically normal individuals as well. However, they are poorly understood.

11 Jul 2011

Migraine News and Research

Latest Migraine News and Research

Allergan receives positive opinion from Irish Medicines Board for BOTOX

Longer looks: Treating Down syndrome?; mentally ill, meds & trials

FDA accepts MAP Pharmaceuticals' LEVADEX NDA for filing

Smoking, high blood pressure and diabetes in middle age linked to brain damage

Statins may help protect young people from future strokes

Merck reports worldwide sales of $12.2 billion for second quarter 2011

POZEN reports revenue of $4.6 million for second quarter 2011

Cognitive behavioral therapy and self-help may improve unexplained symptoms of pain, fatigue

Safeguard Scientifics reports consolidated net income of $121.8M for second quarter 2011

Baxter GAMMAGARD LIQUID for PI receives FDA approval for subcutaneous administration

FDA approves Cephalon's REMS for FENTORA, ACTIQ

Public disclosure of Bachmann's migraine condition raises much-needed awareness

Study examines cost-effectiveness of MS drugs in the U.S.

Scientists analyze structural changes in calcium channels caused by Timothy-mutation

Maintaining general health may help reduce risk for dementia

UW scientists determine atomic architecture of sodium channel

FDA clears St. Jude Medical's Epiducer lead delivery system for neurostimulation

Osteoporosis, low bone density common in people with early-stage MS

FDA approves expansion of St. Jude Medical's BROADEN deep brain stimulation study for depression

Study links OBEs with neural instability and errors in body representation

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Migraine News and Research

Latest Migraine News and Research

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in